To be or not to be…
Maharashtra Food and Drug Administrations's (FDA) decision to forbid Ayurveda, Yoga and Naturopathy, Unani, Siddha, Homeopathy…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Management
Global biotechs financial performance stabilising: EY report
The global biotechnology industry has witnessed a second straight year of increasingly stable financial performance in 2011,…
FSSA and the emerging OTC landscape
Anil Khanna, an independent strategic consultant and investment banker, talks about FSSA guidelines and its implications OTC drugs…
Regulatory woes of pharma SMEs
Jagmohan Rai Agarwal, after elucidating about the regulatory woes of the Indian pharmaceutical industry in the last issue, draws…
ACTA Down, but What Next?
The EU Parliament has rejected the Anti-Counterfeiting Trade Agreement (ACTA), but there are other similar moves to restrict free…
Drug pricing norms: Cost or MRP based?
As the second largest exporter of bulk drugs and largest formulation exporter, the Indian pharmaceutical industry has made its…
Venus Remedies: Reinventing R&D
Generic dominated Indian pharma market also has exceptions like Venus Remedies who wants to make transition from generic to…
Regulatory woes of pharma SMEs (Part I)
Jagmohan Rai Agarwal has experienced the workings of the Indian drug regulatory authorities across the country while engaged in…
Back to the roots Landscaping OTC opportunities in the Indian ayurveda market
Sreedevi Yallamrazu, Senior Strategic Analyst, CubeX comments on the acceptance of traditional medicine for holistic health and…
A holistic view of the HPAPI opportunity
The High Potency Active Pharmaceutical Ingredients (HPAPI) segment is the potential cash cow of the pharma procurement basket but…